Theravance Biopharma, Inc. (TBPH) Shares Bought by Alliancebernstein L.P.

Alliancebernstein L.P. boosted its position in shares of Theravance Biopharma, Inc. (NASDAQ:TBPH) by 9.1% during the second quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 61,235 shares of the biopharmaceutical company’s stock after purchasing an additional 5,100 shares during the quarter. Alliancebernstein L.P. owned approximately 0.11% of Theravance Biopharma worth $2,440,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the business. SG Americas Securities LLC boosted its position in Theravance Biopharma by 8.1% during the second quarter. SG Americas Securities LLC now owns 5,931 shares of the biopharmaceutical company’s stock worth $236,000 after purchasing an additional 443 shares in the last quarter. Parametric Portfolio Associates LLC boosted its position in Theravance Biopharma by 3.3% during the first quarter. Parametric Portfolio Associates LLC now owns 14,090 shares of the biopharmaceutical company’s stock worth $519,000 after purchasing an additional 456 shares in the last quarter. Legal & General Group Plc boosted its position in Theravance Biopharma by 3.7% during the second quarter. Legal & General Group Plc now owns 16,289 shares of the biopharmaceutical company’s stock worth $649,000 after purchasing an additional 576 shares in the last quarter. Swiss National Bank boosted its position in Theravance Biopharma by 1.7% during the first quarter. Swiss National Bank now owns 64,442 shares of the biopharmaceutical company’s stock worth $2,373,000 after purchasing an additional 1,100 shares in the last quarter. Finally, Rhumbline Advisers boosted its position in Theravance Biopharma by 3.8% during the second quarter. Rhumbline Advisers now owns 45,643 shares of the biopharmaceutical company’s stock worth $1,818,000 after purchasing an additional 1,677 shares in the last quarter. Institutional investors own 84.84% of the company’s stock.

In other news, CEO Rick E. Winningham acquired 10,000 shares of the business’s stock in a transaction that occurred on Friday, August 11th. The stock was acquired at an average cost of $24.50 per share, for a total transaction of $245,000.00. Following the completion of the acquisition, the chief executive officer now owns 866,377 shares in the company, valued at $21,226,236.50. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Henrietta Fore acquired 6,000 shares of the business’s stock in a transaction that occurred on Friday, August 11th. The shares were purchased at an average price of $23.99 per share, with a total value of $143,940.00. Following the completion of the acquisition, the director now owns 24,000 shares of the company’s stock, valued at approximately $575,760. The disclosure for this purchase can be found here. In the last ninety days, insiders bought 20,000 shares of company stock valued at $494,300. 6.10% of the stock is currently owned by insiders.

A number of analysts have commented on TBPH shares. Cantor Fitzgerald started coverage on Theravance Biopharma in a research report on Friday, June 16th. They set an “overweight” rating and a $55.00 target price on the stock. ValuEngine upgraded Theravance Biopharma from a “sell” rating to a “hold” rating in a research report on Wednesday, September 13th. Zacks Investment Research upgraded Theravance Biopharma from a “sell” rating to a “hold” rating in a research report on Tuesday, September 19th. Needham & Company LLC restated a “buy” rating on shares of Theravance Biopharma in a research report on Wednesday, August 2nd. Finally, BidaskClub downgraded Theravance Biopharma from a “hold” rating to a “sell” rating in a research report on Thursday, July 27th. Three research analysts have rated the stock with a sell rating, one has assigned a hold rating and five have issued a buy rating to the company’s stock. Theravance Biopharma presently has a consensus rating of “Hold” and an average target price of $45.17.

Theravance Biopharma, Inc. (TBPH) opened at 33.09 on Friday. The company has a 50-day moving average price of $32.77 and a 200 day moving average price of $35.51. The firm’s market capitalization is $1.78 billion. Theravance Biopharma, Inc. has a 1-year low of $23.15 and a 1-year high of $43.44.

ILLEGAL ACTIVITY WARNING: This story was first posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this story on another website, it was copied illegally and reposted in violation of U.S. and international copyright law. The original version of this story can be read at https://www.dispatchtribunal.com/2017/10/14/theravance-biopharma-inc-tbph-shares-bought-by-alliancebernstein-l-p.html.

About Theravance Biopharma

Theravance Biopharma, Inc is a biopharmaceutical company. The Company is engaged in creating medicines for patients suffering from serious illness. The Company operates in the segment of discovery (research), development and commercialization of human therapeutics. The Company’s pipeline of internally discovered product candidates includes medicines to address the unmet needs of patients being treated for serious conditions primarily in the acute care setting.

Want to see what other hedge funds are holding TBPH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Theravance Biopharma, Inc. (NASDAQ:TBPH).

Institutional Ownership by Quarter for Theravance Biopharma (NASDAQ:TBPH)

Receive News & Ratings for Theravance Biopharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Theravance Biopharma Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply